Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Reference Values, Infusions, Intravenous, Intestinal Absorption, Dextran Sulfate, Administration, Oral, Blood Coagulation
Eligibility Criteria
Exclusion Criteria Co-existing Condition: Volunteers with any of the following are excluded: Disorders of coagulation or disorders of plasma lipids. Allergy to dextran sulfate, other sulfates, other dextrans. Concurrent Medication: Excluded: Volunteers who anticipate need for medication during study. Volunteers with any of the following are excluded: Disorders of coagulation or disorders of plasma lipids. Allergy to dextran sulfate, other sulfates, other dextrans. Prior Medication: Excluded within 2 weeks of study entry: Any medication. Risk Behavior: Excluded: Ingestion of alcohol within 48 hours prior to study. History of recent drug or alcohol abuse. Disorders of coagulation or disorders of plasma lipids. Allergy to dextran sulfate, other sulfates, other dextrans. Volunteers selected are: In good general health as determined by screening history, physical examination, and laboratory panel within established limits of normal for hospital laboratory. Consenting volunteers. Available for 6 days of continuous hospitalization.
Sites / Locations
- Johns Hopkins Hosp